Literature DB >> 30890591

Chronic kidney disease, cardiovascular risk markers and total mortality in older men: cystatin C versus creatinine.

Shahrzad Zonoozi1, Sheena E Ramsay2, Olia Papacosta3, Lucy T Lennon3, Elizabeth A Ellins4, Julian P J Halcox4, Peter Whincup5, S Goya Wannamethee3.   

Abstract

BACKGROUND: It remains uncertain whether cystatin C is a superior marker of renal function than creatinine in older adults. We have investigated the association between estimated glomerular filtration rate (eGFR) using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equations based on creatinine (CKD-EPIcr) and cystatin C (CKD-EPIcys), and cardiovascular risk markers and mortality in older adults.
METHODS: This is a cross-sectional and prospective study of 1639 British men aged 71-92 years followed up for an average of 5 years for mortality. Cox survival model and receiving operating characteristic analysis were used to assess the associations.
RESULTS: The prevalence of chronic kidney disease (CKD) was similar using the two CKD-EPI equations, although cystatin C reclassified 43.9% of those with stage 3a CKD (eGFR 45-59 mL/min/1.732, moderate damage) to no CKD. However, CKD stages assessed using both CKD-EPIcr and CKD-EPIcys were significantly associated with vascular risk markers and with all-cause and cardiovascular disease mortality. In all men with CKD (eGFR <60 mL/min/1.732), the HRs (95% CI) for all-cause mortality after adjustment for cardiovascular risk factors compared with those with no CKD were 1.53 (1.20 to 1.96) and 1.74 (1.35 to 2.23) using CKD-EPIcr and CKD-EPIcys, respectively. Comparisons of the two CKD equations showed no significant difference in their predictive ability for mortality (difference in area under the curve p=0.46).
CONCLUSION: Despite reclassification of CKD stages, assessment of CKD using CKD-EPIcys did not improve prediction of mortality in older British men >70 years. Our data do not support the routine use of CKD-EPIcys for identifying CKD in the elderly British male population. © Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  cardiovascular disease; epidemiology; mortality

Mesh:

Substances:

Year:  2019        PMID: 30890591     DOI: 10.1136/jech-2018-211719

Source DB:  PubMed          Journal:  J Epidemiol Community Health        ISSN: 0143-005X            Impact factor:   3.710


  3 in total

1.  Contribution of cystatin C- and creatinine-based definitions of chronic kidney disease to cardiovascular risk assessment in 20 population-based and 3 disease cohorts: the BiomarCaRE project.

Authors:  Dietrich Rothenbacher; Martin Rehm; Licia Iacoviello; Simona Costanzo; Hugh Tunstall-Pedoe; Jill J F Belch; Stefan Söderberg; Johan Hultdin; Veikko Salomaa; Pekka Jousilahti; Allan Linneberg; Susana Sans; Teresa Padró; Barbara Thorand; Christa Meisinger; Frank Kee; Amy Jayne McKnight; Tarja Palosaari; Kari Kuulasmaa; Christoph Waldeyer; Tanja Zeller; Stefan Blankenberg; Wolfgang Koenig
Journal:  BMC Med       Date:  2020-11-09       Impact factor: 8.775

2.  Association of cystatin C levels with metabolic syndrome incidence: a nested case-control study with propensity score matching.

Authors:  Tengfei Yang; Dongmei Pei
Journal:  J Int Med Res       Date:  2021-01       Impact factor: 1.671

3.  Poor Oral Health and Inflammatory, Hemostatic, and Cardiac Biomarkers in Older Age: Results From Two Studies in the UK and USA.

Authors:  Eftychia Kotronia; S Goya Wannamethee; A Olia Papacosta; Peter H Whincup; Lucy T Lennon; Marjolein Visser; Yvonne L Kapila; Robert J Weyant; Sheena E Ramsay
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2021-01-18       Impact factor: 6.053

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.